Allergan Aesthetics is presenting 21 evidence-based e-posters at the Aesthetic & Anti-Aging Medicine World Congress in Monaco from March 26 to 28, 2026, covering clinical, real-world and preclinical findings. The breadth of topics spans investigational neurotoxins, established neuromodulators and soft tissue fillers across global patient populations.

Data show investigational neurotoxin TrenibotulinumtoxinE delivers rapid improvement in moderate-to-severe glabellar lines as early as 8 hours, with a 2–3 week duration and consistent efficacy and safety in East Asian and North American/European cohorts. Pooled analyses indicate high satisfaction in both toxin-naïve and previously treated patients, and support sequential use with onabotulinumtoxinA.

Real-world studies confirm onabotulinumtoxinA achieves high patient satisfaction, natural-looking results and improvements in psychological well-being for upper facial lines. Long-term use often leads patients to adopt additional aesthetic procedures, reinforcing its role as the foundation for multimodal treatment plans.

Evidence for hyaluronic acid injectables VYC-12L and VYC-20L demonstrates up to six months of sustained improvement in neck lines, perioral lines and overall skin quality with favorable tolerability. These findings highlight continued investment in integrated, patient-centric aesthetic solutions across Allergan Aesthetics’ portfolio.